Cargando…
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept
BACKGROUND: Immune checkpoint inhibitors (ICI) may cause pneumonitis, resulting in potentially fatal lung inflammation. However, distinguishing pneumonitis from pneumonia is time-consuming and challenging. To fill this gap, we build an image-based tool, and further evaluate it clinically alongside r...
Autores principales: | Aminu, Muhammad, Daver, Naval, Godoy, Myrna C. B., Shroff, Girish, Wu, Carol, Torre-Sada, Luis F., Goizueta, Alberto, Shannon, Vickie R., Faiz, Saadia A., Altan, Mehmet, Garcia-Manero, Guillermo, Kantarjian, Hagop, Ravandi-Kashani, Farhad, Kadia, Tapan, Konopleva, Marina, DiNardo, Courtney, Pierce, Sherry, Naing, Aung, Kim, Sang T., Kontoyiannis, Dimitrios P., Khawaja, Fareed, Chung, Caroline, Wu, Jia, Sheshadri, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570510/ https://www.ncbi.nlm.nih.gov/pubmed/37841255 http://dx.doi.org/10.3389/fimmu.2023.1249511 |
Ejemplares similares
-
Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021) -
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021) -
Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019) -
Resistance to targeted therapies: delving into FLT3 and IDH
por: Desikan, Sai Prasad, et al.
Publicado: (2022) -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)